Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

63 results about "SIRT6" patented technology

Sirtuin 6 (SIRT6 or Sirt6) is a stress responsive protein deacetylase and mono-ADP ribosyltransferase enzyme encoded by the SIRT6 gene. SIRT6 functions in multiple molecular pathways related to aging, including DNA repair, telomere maintenance, glycolysis and inflammation.

Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders

A method of inducing NAD+ synthesis in a subject. The method comprises administering to the subject a therapeutically effective amount of resveratrol or a functionally equivalent analogue or derivative thereof. NAD+ synthesis increases the activity of Poly(ADP-ribose) polymerase (PARP) enzymes and sirtuin enzymes. The PARP enzyme is PARP-1 or PARP-2 and the sirtuin enzyme is selected from the group consisting of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.
Owner:NAD LIFE

Markers for endometrial cancer

The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and / or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values.; Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.
Owner:GEADIC BIOTEC AIE

Application of vascular endothelial cell SIRT6 gene, and drug

The invention discloses an application of a vascular endothelial cell SIRT6 gene, and a drug, and belongs to the field of functions and applications of genes. Endothelial cell-specific SIRT6 knockoutmice are used as experimental subjects, and a result of comparison of the experimental subjects and a control group SIRT6flox / flox mice shows that the vascular endothelial NO release level and the NOSenzyme activity of the endothelial cell-specific SIRT6 knockout mice are significantly reduced, the vasodilation function and the barrier function of the endothelial cell-specific SIRT6 knockout miceare impaired, so the loss of SIRT6 in endothelial cells can lead to severe endothelial dysfunction, thereby leading to other cardiovascular diseases. The SIRT6 gene has a protective effect on the endothelial function, and provides a theoretical basis and a clinical basis for the role of the SIRT6 in the research of new targets and strategies for preventing and treating the cardiovascular diseases.
Owner:XI AN JIAOTONG UNIV

Methods for the use of 5'-adenosine diphosphate ribose (ADPR)

ActiveUS20190298752A1Organic active ingredientsNervous disorderHerpes simplex virus DNAAdenosine diphosphate ribose
The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Owner:INVIRSA INC

Quinoline-4-carboxamide skeleton derivative and application thereof

The invention discloses a quinoline-4-formamide skeleton derivative and application thereof, belonging to the field of chemical medicines. The invention provides a compound as shown in a formula I or pharmaceutically acceptable salt thereof. The invention also provides a preparation method and application of the compound. Biological experiments show that the compound has a very good excitation effect on SIRT6, shows good same-family selectivity and can obviously improve pathological changes related to SIRT 6at an in-vitro molecular level; and particularly, the compound shows good anti-cancer activity in vivo and in vitro, especially pancreatic cancer activity, provides a new choice for development and application of anti-cancer drugs, and has good application prospects.
Owner:SICHUAN UNIV

Gene modified mesenchymal stem cell as well as preparation method and application thereof

The invention belongs to the technical field of biology, and particularly relates to a genetically modified mesenchymal stem cell as well as a preparation method and application thereof. The invention relates to a gene modified mesenchymal stem cell, the gene modified mesenchymal stem cell is a mesenchymal stem cell of an over-expression SIRT6 gene, and the acquisition number of the SIRT6 on NCBI (National Center of Biotechnology Information) is NM001193285. The invention finds that SIRT6 is helpful for delaying the cell senescence process and obviously improving the anti-senescence capability of cells by regulating senescence-related genes and proteins.
Owner:BAIOPAI (TIANJIN) BIOTECHNOLOGY CO LTD +1

Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Owner:INVIRSA INC

Application of wnt inhibitor in preparation of medicine for treating hematopoietic aplastic disorders

ActiveCN105854018BPromote regenerationPromote regeneration of knockout hematopoietic stem cellsTetrapeptide ingredientsGene therapyDiseaseMechanism of action
The invention discloses an application of a Wnt inhibitor ICG001 in the preparation of medicines for treating hematopoietic aregenerative diseases. The Wnt inhibitor ICG001 can inhibit a CBP mediated Wnt signal path in order to inhibit depletion of too high Wnt signal hematopoietic stem cells, induced by SIRT6 deletion. The invention discloses the application of the Wnt inhibitor ICG001 in the preparation of the medicines for treating hematopoietic aregenerative diseases, and an action mechanism of the ICG001 in promotion of regeneration of SIRT6 knockout hematopoietic stem cells.
Owner:佳康赛尔生物技术(云南)有限公司

Application of Wnt inhibitor in preparation of medicines for treating hematopoietic aregenerative diseases

ActiveCN105854018APromote regenerationPromote regeneration of knockout hematopoietic stem cellsTetrapeptide ingredientsGene therapyDiseaseWnt inhibitor
The invention discloses an application of a Wnt inhibitor ICG001 in the preparation of medicines for treating hematopoietic aregenerative diseases. The Wnt inhibitor ICG001 can inhibit a CBP mediated Wnt signal path in order to inhibit depletion of too high Wnt signal hematopoietic stem cells, induced by SIRT6 deletion. The invention discloses the application of the Wnt inhibitor ICG001 in the preparation of the medicines for treating hematopoietic aregenerative diseases, and an action mechanism of the ICG001 in promotion of regeneration of SIRT6 knockout hematopoietic stem cells.
Owner:佳康赛尔生物技术(云南)有限公司

Substituted 6,8-dimercapto-2-phenyl-4H-chromen-4-one derivative and preparation method and application thereof

The invention belongs to the field of organic synthetic medicine and particularly relates to a substituted 6,8-dimercapto-2-phenyl-4H-chromen-4-one derivative, having the structure that is shown in the description. Embodiments of the substituted 6,8-dimercapto-2-phenyl-4H-chromen-4-one derivative prove that the derivative can activate TyrRS-PARP-1 signal pathway such that activation of PARP-1 viaTyrRS leads to a series of protective genes, including tumor inhibiting gene p53 and longevity genes FOXO3A and SIRT6 to be activated; the derivative has good medicinal potential in age defying and DNA restoration drugs, and a new potential option is provided for clinical medication; in addition, a preparation method of a new compound herein is simple, the preparation method has mild reaction conditions, is convenient to perform and control, has low energy consumption, high yield and low cost, and is suitable for industrial production, and the compound produced has high bioactivity, high activity and selectivity, significant drug-likeness, and promising market prospect.
Owner:SICHUAN UNIV

A viral vector comprising SIRT6 for treating a disease

PCT designated stage expiredWO2025032584A1Senses disorderNervous disorderDiseasePolynucleotide
The invention concerns recombinant adeno-associated virus (rAAV) vectors comprising a polynucleotide sequence encoding a SIRT6 protein, wherein said polynucleotide sequence encoding a SIRT6 protein is codon-optimized for obtaining molecules with a customized stability, translation efficiency and / or reduced immunogenicity. As well as uses and methods employing the rAAV vectors for treating various diseases.
Owner:SIRT6 LTD

Methods for the use of 5'-adenosine diphosphate ribose (ADPR)

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Owner:INVIRSA INC

Deuterated analogs of sirtuin 6 modulator IMU-856

The present disclosure relates to novel deuterated analogs of the sirtuin 6 (SIRT6) modulator IMU-856, pharmaceutical formulations comprising them, a process for their preparation and their use as medicament, alone or in combination with one or more additional agents, for preventing and / or treating of various diseases, wherein the modulation of SIRT6 is desirable, e.g. in celiac disease.
Owner:IMMUNIC AG

Compositions and methods for treating loss of pleasant sensation

The present invention relates to methods of treating pleasant sensation loss in a human subject by administering a SIRT6 activator. The invention also provides methods of treating a pleasant sensation loss in a human female subject by administering a SIRT6 activator, wherein the female subject can be recognized by, for example, the presence of two X chromosomes or circulating a female hormone.
Owner:HITSEY PHARMACEUTICALS

Medicament for treating atherosclerosis and application of Sirt6

The invention relates to an application of Sirt6 in regulating cell autophagy. The invention further relates to application of the Sirt6 in preparation of a medicament for treating atherosclerosis caused by diabetes. The invention also relates to a medicament for treating atherosclerosis caused by diabetes. The medicament comprises an expression vector with a Sirt6 gene overexpression cassette. According to the application, the influence of the Sirt6 on the deacetylation of the Caveolin-1 protein in the vascular endothelial cells is found for the first time, and the condition that the deacetylation level of the Caveolin-1 protein in the vascular endothelial cells can be changed by adjusting the expression quantity of the Sirt6, so that the autophagy effect and the atherosclerosis process in the cells are influenced is found. Therefore, the invention has important significance and enlightenment for treating atherosclerosis caused by diabetes.
Owner:华中科技大学同济医学院附属梨园医院

Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Owner:INVIRSA INC

Nano drug-loaded complex with targeted myocardial function as well as preparation method and application of nano drug-loaded complex

The invention relates to a nano drug-loaded complex with a targeted myocardial function as well as a preparation method and application of the nano drug-loaded complex. The preparation method comprises the following steps: constructing a novel, safe and efficient nano drug-loaded complex by utilizing a nano material assembly technology, namely preparing phospholipid micelles by taking distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) as a main raw material, loading fluorescent coumarin 6 (C6), adding ischemia targeting polypeptide CSTSMLKAC (PEP) to be coupled on the outer side of the DSPE-PEG, wrapping an SIRT6 agonist MDL-800 in the DSPE-PEG, and preparing the novel, safe and efficient nano drug-loaded complex. The preparation method comprises the following steps: designing and constructing to obtain a DSPE-PEG-C6-PEP-MDL-800 (DPCP-MDL-800) complex; on the basis, characterization release and in-vivo distribution of the complex and an improvement effect of the complex on myocardial ischemia reperfusion injury of an aged mouse are evaluated. The novel nano drug-loaded complex drug with the ischemic myocardial targeting function provided by the invention is expected to provide a potential solution for myocardial ischemia reperfusion injury of aged mice.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

sirt6 small molecule agonist and its application

ActiveCN109384694BAgonist activityOvert agonistic activityOrganic active ingredientsOrganic chemistryCarboxyl radicalPharmacometrics
The invention discloses a SIRT6 small molecule agonist and an application thereof. The agonist is a tricyclic bissulfonamide derivative represented by formula (1) or a pharmacologically acceptable salt thereof, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 The same or different, represents hydrogen atom, halogen, said halogen refers to fluorine, chlorine, bromine and iodine, hydroxyl, nitro, amino, carboxyl, acid ester, sulfonamide, mercapto, methoxy, ethoxy, benzyloxy base, methyl, tert-butyl, cyano; R 11 Represents a hydrogen atom, chlorine, nitro, amino, benzyl alcohol, benzyl chloride, benzylamine, carboxyl, and acid ester. The three rings are connected by amide bonds. The invention designs and synthesizes a high-efficiency and low-toxicity SIRT6 small molecule agonist, which can obviously stimulate the activity of SIRT6 in an in vitro experiment, and is of great significance to the development of drugs for related diseases.
Owner:上海宇道生物技术有限公司

Urea compounds having substituents

The present invention aims to provide a compound useful as an active ingredient for the prevention and treatment of inflammatory diseases, wherein the compound contains a specific chemical structure having a SIRT6 activation effect. The present invention relates to a compound of formula (1) or a pharmaceutically acceptable salt thereof. (The symbols in formula (1) are the same as those defined in the specification.)#imgabs0#
Owner:DAIICHI SANKYO CO LTD

Sirtuin 6 protein deacylase (SIRT6) activators

The present disclosure provides compounds according to Formula I and pharmaceutically acceptable salts thereof, as well as compositions including such compounds and a pharmaceutically acceptable carrier or excipient. Further provided are methods of inactivating SIRT6 with compounds of Formula I as well as compounds of Formula III, W2—R2—Y—R3, as described herein. In addition, the present technology provides methods of treatment using such compounds to lower LDL levels, lower triglyceride levels, and / or increase glucose tolerance in a subject, and / or to inhibit proliferation of ovarian, colorectal, hepatocellular, non-small cell lung, glioblastoma, osteosarcoma, pancreatic, and skin cancer cells, and / or inhibit liver and / or kidney fibrosis, and / or promote corneal epithelial wound healing.
Owner:WISCONSIN ALUMNI RES FOUND

Compositions and methods for treating joint and bone diseases

This invention relates to a method of treating a joint and / or bone disease, slowing progression of a reduction in bone mass, increasing osteoblast formation, decreasing osteoclast formation, and / or reducing osteocyte death, slowing progression of a reduction in joint mobility and / or function, slowing progression of a reduction in cartilage, and / or reducing chondrocyte senescence and / or death by administering a therapeutically effective amount of a SIRT6 activator, optionally with nicotinamide adenine dinucleotide (NAD+) and / or an NAD+ precursor.
Owner:SIRTSEI PHARMACEUTICALS INC

Beta-carboline 3, 6, 9-position modified derivative as well as preparation method and application thereof

The invention relates to a beta-carboline 3, 6, 9-position modified derivative as well as a preparation method and application thereof, and belongs to the technical field of natural medicines and medicinal chemistry. In particular to a beta-carboline 3, 6, 9-position modified derivative or pharmaceutically acceptable salt thereof, further provides a pharmaceutical composition, provides a preparation method of the beta-carboline 3, 6, 9-position modified derivative, and also provides application of the beta-carboline 3, 6, 9-position modified derivative in preparation of SIRT6 inhibitors or tumor treatment drugs. The beta-carboline 3, 6, 9-position modified derivative or the pharmaceutically acceptable salt thereof disclosed by the invention is shown as a general formula I in the specification. Wherein X, n, R1, R2 and R3 are as described in the claims and the specification. # imgabs0 #
Owner:SHENYANG PHARMA UNIV

Methods for the use of 5'-adenosine diphosphate ribose (ADPR)

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
Owner:INVIRSA INC

Compositions and methods for controlling glucose levels

The present invention relates to a method for improving glucose homeostasis and / or lowering plasma glucose levels by administering a SIRT6 activator. The present invention also provides a method for treating hyperglycemia, prediabetes, and diabetes, including type I diabetes, type II diabetes, or gestational diabetes, by administering a SIRT6 activator.
Owner:SIRTSEI PHARMACEUTICALS INC

Application of SIRT6 protein as a marker for detecting diabetic cataract and preparing drugs for preventing and treating diabetic cataract

ActiveCN114878835BSenses disorderMetabolism disorderDiseaseLens epithelial cell proliferation
The present invention belongs to the field of biomedicine technology, and specifically relates to the use of SIRT6 protein as a marker for detecting diabetic cataracts and in the preparation of drugs for preventing and treating diabetic cataracts. The SIRT6 protein provided by the present invention is significantly downregulated in the target cell lens epithelial cells of diabetic cataracts, and thus can be used as a marker for detecting diabetic cataracts. At the same time, overexpression of SIRT6 protein in diabetic cataract target cells can promote the expression of autophagy factors in diabetic cataract target cells and increase the proliferation activity of lens epithelial cells, protect the normal metabolism of lens epithelial cells, and play a role in alleviating the progression of the disease in diabetic cataracts. Therefore, SIRT6 protein can be used as a therapeutic target for diabetic cataracts.
Owner:NINGXIA MEDICAL UNIV